Technical Analysis for EBS - Emergent Biosolutions, Inc.

Grade Last Price % Change Price Change
grade F 43.32 -2.08% -0.92
EBS closed down 2.12 percent on Monday, May 20, 2019, on 68 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical EBS trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.05%
Narrow Range Bar Range Contraction 0.05%
NR7 Range Contraction 0.05%
New 52 Week Low Weakness 0.05%
Wide Bands Range Expansion 0.05%
Gapped Down Weakness 0.05%
Oversold Stochastic Weakness 0.05%
Oversold Stochastic Weakness -2.08%
180 Bearish Setup Bearish Swing Setup -4.24%
Slingshot Bearish Bearish Swing Setup -4.24%

Older signals for EBS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Emergent BioSolutions, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and commercialization of specialized products for use in defense and commercial markets in the United States and internationally. The company operates in two segments, Biodefense and Biosciences. It markets BioThrax, an FDA licensed vaccine for the prevention of anthrax disease; and RSDL (decontamination lotion) product for removal or neutralization of chemical warfare agents from the skin. The company's development pipeline includes Anthrivig (Human Anthrax Immunoglobulin), a polyclonal anthrax therapeutic candidate; PreviThrax, a recombinant anthrax vaccine candidate, NuThrax (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant); BioThrax with a novel adjuvant; and Thravixa (Fully Human Anthrax Monoclonal Antibody), a therapeutic being studied for use against symptomatic anthrax infection. In addition, it develops TRU-016, a humanized anti-CD37 therapeutic candidate, based on its ADAPTIR (Modular Protein Technology) platform that is in Phase I/II clinical trials to treat chronic lymphocytic leukemia. Further, the company develops preclinical product candidates targeted for solid tumors, inflammatory bowel disease, graft versus host disease, rheumatoid arthritis, and a human vaccine to protect against influenza caused by a range of circulating H5 influenza strains. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Rockville, Maryland.
Medicine Medical Specialties Pharmaceutical Drugs Solid Tumors Influenza Rheumatoid Arthritis Inflammatory Bowel Disease Vaccination FDA Chronic Lymphocytic Leukemia Vaccines Biological Warfare Anthrax Chemical Warfare Agents Preclinical Preclinical Product
Is EBS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 73.89
52 Week Low 43.26
Average Volume 595,679
200-Day Moving Average 59.5598
50-Day Moving Average 50.5368
20-Day Moving Average 48.9465
10-Day Moving Average 45.676
Average True Range 1.9538
ADX 33.72
+DI 11.3383
-DI 29.8188
Chandelier Exit (Long, 3 ATRs ) 48.7086
Chandelier Exit (Short, 3 ATRs ) 49.1214
Upper Bollinger Band 56.3295
Lower Bollinger Band 41.5635
Percent B (%b) 0.12
BandWidth 30.167632
MACD Line -2.2991
MACD Signal Line -1.7839
MACD Histogram -0.5152
Fundamentals Value
Market Cap 1.78 Billion
Num Shares 41.1 Million
EPS 1.57
Price-to-Earnings (P/E) Ratio 27.58
Price-to-Sales 3.22
Price-to-Book 2.65
PEG Ratio 1.56
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 44.50
Resistance 3 (R3) 44.62 44.34 44.30
Resistance 2 (R2) 44.34 44.03 44.28 44.23
Resistance 1 (R1) 43.82 43.85 43.68 43.70 44.17
Pivot Point 43.54 43.54 43.47 43.48 43.54
Support 1 (S1) 43.02 43.23 42.88 42.90 42.43
Support 2 (S2) 42.74 43.05 42.68 42.37
Support 3 (S3) 42.22 42.74 42.30
Support 4 (S4) 42.10